Inflammatory activity assessment by F18 FDG-PET/CT in persistent symptomatic sarcoidosis

FDG PETCT in colorectal cancer

Colorectal cancer represents the second most common malignancy worldwide, with approximately one million newly diagnosed cases each year, and is the fourth leading cause of cancer mortality. This article provides an overview of the role of FDG (fluorodeoxyglucose) PET (positron emission tomography) CT (computed tomography) for assessment in patients with colorectal cancer. A summary of key lear...

Apsr Respiratory Updates

Idiopathic Pulmonary Fibrosis: Clinically Meaningful Primary Endpoints in Phase 3 Clinical Trials 3 Hot on the breath: Mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good 4 Idiopathic Pulmonary Fibrosis: Lung Function is a Clinically Meaningful Endpoint for Phase 3 Trials 4 III. About Sarcoidosis 5 A Novel Sarcoidosis Risk Locus for Europeans on Chromosom...

Reduced-dose [F]-FDG PETCT scanning with current generation PETCT systems

F 18 FDG PETCT detection for liver metastases

Scar sarcoidosis on 18F-FDG PET/CT

18F-labeled fluoro-2-deoxyglucose positron emission tomography/ computed tomography (18F-FDG PET/CT) is an important imaging modality in the clinical workup of patients with chronic inflammatory disorders which present quite often with a fever of unknown origin. Sarcoidosis is a multisystem chronic inflammatory disorder with a wide clinical spectrum that can involve different organs. The diagno...